US2004242487A1PendingUtilityA1

Regulation of eating behavior

49
Assignee: JOSLIN DIABETES CT INC A MASSAPriority: Jun 6, 1995Filed: Jul 7, 2004Published: Dec 2, 2004
Est. expiryJun 6, 2015(expired)· nominal 20-yr term from priority
Inventors:Eleftheria Maratos-FlierJeffrey S. Flier
A61P 5/00A01K 2217/05A61K 48/00C07K 14/575A61K 38/00A61P 3/04
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

MCH and anlogs thereof in the regulation of eating and weight.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 - 29  (Canceled).  
     
     
         30 . A method of inhibiting appetite, or the gain of weight, in a subject comprising: 
 identifying a subject in need of inhibiting appetite or weight gain; and    administering an effective amount of an antagonist of melanocyte concentrating hormone (MCH) to said subject, wherein the antagonist binds an MCH receptor.    
     
     
         31 . The method of  claim 30 , wherein the antagonist binds competitively to an MCH receptor.  
     
     
         32 . The method of  claim 30 , wherein the antagonist binds non-competitively to an MCH receptor.  
     
     
         33 . The method of  claim 30 , wherein the antagonist is a peptide analog of MCH.  
     
     
         34 . The method of  claim 33 , wherein the peptide analog has 1, 2, 3, 4, 5 or more residues within the MCH ring structure modified or substituted with a nonconserved amino acid.  
     
     
         35 . The method of  claim 34 , wherein between 1 and 5 residues within the MCH ring structure modified or substituted with a nonconserved amino acid.  
     
     
         36 . The method of  claim 33 , wherein the peptide analog is deleted for any or all of the residues between R1 and R6 or between R18 and R19.  
     
     
         37 . The method of  claim 34 , wherein the peptide analog is deleted for any or all of the residues between R1 and R6 or between R18 and R19.  
     
     
         38 . The method of  claim 35 , wherein the peptide analog is deleted for any or all of the residues between R1 and R6 or between R18 and R19.  
     
     
         39 . The method of  claim 33 , wherein the peptide analog has least 50% homology with MCH.  
     
     
         40 . The method of  claim 33 , wherein the peptide analog has least 60% homology with MCH.  
     
     
         41 . The method of  claim 33 , wherein the peptide analog has least 70% homology with MCH.  
     
     
         42 . The method of  claim 33 , wherein the peptide analog has least 80% homology with MCH.  
     
     
         43 . The method of  claim 33 , wherein the peptide analog has least 90% homology with MCH.

Join the waitlist — get patent alerts

Track US2004242487A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.